BACKGROUND: to evaluate the safety and efficacy of a physical activity program (PAP) in children and adolescents with cancer. METHODS:children and adolescents with cancer were randomly assigned in a 1:1 ratio to the six-month PAP (intervention group) or to the control group. The first evaluation was performed at the end of the PAP (T0 + 6 mo). At T0 + 6 mo, both groups received the six-month PAP with a second evaluation at T0 + 12 mo. The primary outcome was the evolution of exercise capacity measured using the six-minute walk test (6 MWT) at T0 + 6 mo. Secondary outcomes included PAP safety and changes in other physical functions, self-esteem, and quality-of-life parameters. RESULTS: The trial involved 80 children and adolescents (age range 5.0-18.4 years), of whom 41 were assigned to the interventional group and 39 to the control group. Underlying malignancies were leukemia (39%) and a broad range of solid tumors (61%). No adverse events occurred. At T0 + 6 mo, the evolution of the 6 MWT distance (±SEM) was improved in the intervention group vs. the control group (86 ± 12 m vs. 32 ± 6 m, p < 0.001). Several other physical parameters were significantly improved in the intervention group. Global self-esteem and parent-reported quality-of-life were significantly increased in the intervention group. Analysis at T0 + 12 mo showed persistence of the benefits in the intervention group on exercise capacity evolution (115 ± 18 m vs. 49 ± 11 m, p = 0.004) and on most physical and QoL parameters. CONCLUSION: In children and adolescents with cancer, a physical activity program is safe, improves exercise capacity, and may have physical and psychological benefits.
RCT Entities:
BACKGROUND: to evaluate the safety and efficacy of a physical activity program (PAP) in children and adolescents with cancer. METHODS:children and adolescents with cancer were randomly assigned in a 1:1 ratio to the six-month PAP (intervention group) or to the control group. The first evaluation was performed at the end of the PAP (T0 + 6 mo). At T0 + 6 mo, both groups received the six-month PAP with a second evaluation at T0 + 12 mo. The primary outcome was the evolution of exercise capacity measured using the six-minute walk test (6 MWT) at T0 + 6 mo. Secondary outcomes included PAP safety and changes in other physical functions, self-esteem, and quality-of-life parameters. RESULTS: The trial involved 80 children and adolescents (age range 5.0-18.4 years), of whom 41 were assigned to the interventional group and 39 to the control group. Underlying malignancies were leukemia (39%) and a broad range of solid tumors (61%). No adverse events occurred. At T0 + 6 mo, the evolution of the 6 MWT distance (±SEM) was improved in the intervention group vs. the control group (86 ± 12 m vs. 32 ± 6 m, p < 0.001). Several other physical parameters were significantly improved in the intervention group. Global self-esteem and parent-reported quality-of-life were significantly increased in the intervention group. Analysis at T0 + 12 mo showed persistence of the benefits in the intervention group on exercise capacity evolution (115 ± 18 m vs. 49 ± 11 m, p = 0.004) and on most physical and QoL parameters. CONCLUSION: In children and adolescents with cancer, a physical activity program is safe, improves exercise capacity, and may have physical and psychological benefits.
Authors: William B Strong; Robert M Malina; Cameron J R Blimkie; Stephen R Daniels; Rodney K Dishman; Bernard Gutin; Albert C Hergenroeder; Aviva Must; Patricia A Nixon; James M Pivarnik; Thomas Rowland; Stewart Trost; François Trudeau Journal: J Pediatr Date: 2005-06 Impact factor: 4.406
Authors: Kirsten K Ness; Melissa M Hudson; Jill P Ginsberg; Rajaram Nagarajan; Sue C Kaste; Neyssa Marina; John Whitton; Leslie L Robison; James G Gurney Journal: J Clin Oncol Date: 2009-03-30 Impact factor: 44.544
Authors: Carmen Fiuza-Luces; Julio R Padilla; Luisa Soares-Miranda; Elena Santana-Sosa; Jaime V Quiroga; Alejandro Santos-Lozano; Helios Pareja-Galeano; Fabián Sanchis-Gomar; Rosalía Lorenzo-González; Zoraida Verde; Luis M López-Mojares; Alvaro Lassaletta; Steven J Fleck; Margarita Pérez; Antonio Pérez-Martínez; Alejandro Lucia Journal: Med Sci Sports Exerc Date: 2017-02 Impact factor: 5.411
Authors: Lars Bo Andersen; Maarike Harro; Luis B Sardinha; Karsten Froberg; Ulf Ekelund; Søren Brage; Sigmund Alfred Anderssen Journal: Lancet Date: 2006-07-22 Impact factor: 79.321
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079
Authors: Katja I Braam; Elisabeth M van Dijk-Lokkart; Gertjan J L Kaspers; Tim Takken; Jaap Huisman; Laurien M Buffart; Marc B Bierings; Johannes H M Merks; Marry M van den Heuvel-Eibrink; Margreet A Veening; Eline van Dulmen-den Broeder Journal: BMC Cancer Date: 2018-12-27 Impact factor: 4.430
Authors: Javier S Morales; Pedro L Valenzuela; Daniel Velázquez-Díaz; Adrián Castillo-García; David Jiménez-Pavón; Alejandro Lucia; Carmen Fiuza-Luces Journal: Cancers (Basel) Date: 2021-12-24 Impact factor: 6.639